Developing antibodies to protect against various coronaviruses
Engineering Immunity for Broad Protection Against Betacoronaviruses
This study is working on developing new antibodies that can help protect people from different types of coronaviruses, including the one that causes COVID-19, by targeting a key part of the virus, so that even if the virus changes, the treatment can still work well.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albert Einstein College of Medicine NIH-funded |
| Lab location | 1 site (Bronx, United States) |
| Project ID | NIH-10984676 on NIH RePORTER |
What this research studies
This research focuses on creating new antibodies that can provide broad protection against multiple types of coronaviruses, including those that have caused significant outbreaks like SARS-CoV-2. The approach involves identifying and designing antibodies that target a specific part of the virus known as the spike protein, which is crucial for the virus to enter human cells. By using various laboratory techniques, the researchers will assess how effective these antibodies are in neutralizing the virus and activating the immune response. This work aims to develop therapies that remain effective even as the virus mutates.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of severe illness from coronaviruses, including those with underlying health conditions or those in high-exposure environments.
Not a fit: Patients who are not at risk for coronavirus infections or those who have already been vaccinated with effective vaccines may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective vaccines and treatments for current and future coronavirus infections.
How similar studies have performed: Previous research has shown promise in developing broadly acting antibodies for viral infections, indicating potential success for this novel approach.
Where this research is happening
Bronx, United States
- Albert Einstein College of Medicine — Bronx, United States (Active)
Researchers
- Principal investigator: Miller, Emily Happy — Albert Einstein College of Medicine
- Study coordinator: Miller, Emily Happy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.